AstraZeneca announced new SEROQUEL XR™ (extended release quetiapine fumarate) clinical study data in patients with Generalised Anxiety Disorder (GAD), presented at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. In this study, extended release quetiapine fumarate significantly improved symptoms of anxiety at Week 8 compared with placebo and this was observed as early as day 4. The active comparator arm, escitalopram 10mg/day, was also effective at improving symptoms of GAD at week 8 compared with placebo although improvement was not observed at day 4.
During their lifetimes, it is estimated between 2.7% and 5.4% of people in Europe will suffer from GAD.1 Characteristic symptoms include chronic anxiety, exaggerated worry and tension - it is often accompanied by depression or other anxiety disorders2,3 - and it has a substantial negative impact on Health-Related Quality of Life (HRQoL), productivity at work (including absenteeism) and healthcare costs1.
Antidepressants (SSRIs (selective-serotonin reuptake inhibitors) and SNRIs (serotonin and norepinephrine reuptake inhibitors)) are standard treatments that are generally effective but approximately 30 percent of patients treated with SSRIs or SNRIs will have an inadequate response4. Additionally, they may have a relatively slow onset of action, sometimes requiring combination with a short course of benzodiazepines (BZDs) to achieve initial symptom control - however, BZDs may have the potential for dependence and withdrawal symptoms5.
Buy generic ultram The data presented today in Barcelona are the results of Study 10 - conducted across 64 centres in the U.S. and part of the clinical development programme for extended release quetiapine fumarate for the treatment of GAD6. A total of 854 patients aged 18-65 with a DSM-IV3 diagnosis of GAD were randomized to receive either extended release quetiapine fumarate 150mg/day (n=219), 300mg/day (n=207), escitalopram 10mg/day (n=213) or placebo (n=215). At week 8, extended release quetiapine fumarate 150mg/day, 300mg/day and escitalopram 10mg/day, significantly reduced mean Hamilton Anxiety Rating Scale (HAM-A) total scores from randomization compared with placebo (-13.9 [pBuy propecia pills | Generic soma pills no prescription | Buy generic viagra